HOME >> BIOLOGY >> NEWS
University of Rochester scientists test new method to attack cancer

NOTE: This release has been updated since its original posting.

Scientists have used a technique called RNA interference to impair cancer cells' ability to produce a key enzyme called telomerase. The enzyme, present in most major types of cancer cells, gives cells the lethal ability to divide rampantly without dying. The laboratory experiments create an opportunity for researchers who are focusing on telomerase in a bid to develop a drug like none ever developed - one capable of killing 85 percent of cancers

The research, led by Peter T. Rowley, M.D., of the University of Rochester Medical Center, is being presented today at the annual meeting of the American Association for Cancer Research in Washington, D.C.

The enzyme telomerase produces telomeres, located at the ends of each chromosome, which protect the ends of chromosomes as cells divide. In a normal cell, the telomeres shorten each time the cell divides. After a cell divides 50 to 100 times, the telomeres shorten so much that they can no longer protect the chromosome, and the cell eventually dies.

Scientists believe that such cell death is normal, even healthy. But as a healthy cell turns cancerous, a genetic mutation triggers the production of telomerase, which restores the telomeres to normal length. The restored telomeres enable the cell to divide, unchecked, thousands of times instead of the usual 50 to 100. Over time, a few cancer cells can multiply into a golf-ball-sized tumor or spread to other parts of the body.

Since researchers discovered the important role telomerase plays in most cancers in the mid-1990s, much attention has been focused on finding a way to attack them. Several methods are in various stages of development.

The University of Rochester team used RNA interference to disrupt the production of telomerase in various cancer cells including colon, skin, cervical, and lung cancer. They crafted tiny snippets of double-
'"/>

Contact: Christopher DiFrancesco
chris_difrancesco@urmc.rochester.edu
585-273-4790
University of Rochester Medical Center
14-Jul-2003


Page: 1 2

Related biology news :

1. Indiana University, EPA to study airborne PCBs
2. University of Alberta researcher looks for clues to mysterious disease
3. Northeastern University receives $12.4 million NSF grant for creation of nanomanufacturing institute
4. Washington University in St. Louis leads group studying aging process
5. Tufts University establishes $4 million dollar tissue engineering resource center
6. Case for IBD combination therapy comes from research at Baylor, MIT and Hebrew University
7. As informatics grows, Indiana University helps set research agenda
8. University of Arizona licenses patent for natural fungicide
9. Washington University in St. Louis plays key role in sequencing moss genome
10. University of Pittsburgh receives $10 million grant for head and neck cancer
11. Clemson University spin-off uses corn to make plastics, provide cleaner air

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: University Rochester scientists test new method attack cancer

(Date:5/19/2015)... 2015 Research and ... of the  "Genetic Testing Market Outlook 2018" ... , ,A recent report, Genetic Testing Market ... the current and future genetic testing market. ... working principles and types are covered in ...
(Date:5/14/2015)... , May 14, 2015  Verificient ... identity verification and online remote proctoring, announced ... software-as-a-service (SaaS) company and creator of the ... of the two companies will benefit from ... Canvas. As a fully integrated ...
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
(Date:5/27/2015)... , May 26, 2015 Research ... of the "Global Breast Cancer Monoclonal Antibodies ... Globally, Roche seems to dominate the ... inventory. Its block buster molecule, Herceptin has been ... It was found that breast cancer cells become ...
(Date:5/27/2015)... Fla. (PRWEB) May 27, 2015 Expanding ... dental cement manufacturer Avalon Biomed Inc. recently ... of Mokuda Dental Co. Ltd. , the largest ... inroad into the international market for Avalon Biomed, which ... Plus®, award-winning tricalcium silicate-based dental cements that have won ...
(Date:5/27/2015)... Israel , May 27, 2015  Tikcro Technologies ... quarter ended March 31, 2015. ... quarter, we continued pre-clinical work to generate functional specific ... an early stage, we are encouraged by the development ... field as new antibodies which modulate immune checkpoints gain ...
(Date:5/27/2015)... MB (PRWEB) May 27, 2015 ... data to combat disease, Cubresa Inc. today announced ... “Our MR Compatible in-bore PET Scanner uses silicon ... into single-purpose preclinical MRI machines from manufacturers like ... Cubresa, headquartered in Winnipeg, Canada. “This enables simultaneous ...
Breaking Biology Technology:Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 2Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 3Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 2Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 3Tikcro Technologies Reports First Quarter 2015 Results 2Tikcro Technologies Reports First Quarter 2015 Results 3Cubresa Launches Simultaneous PET/MRI Technology 2
Cached News: